


Vazegepant hydrochloride

Cat. No.:	HY-132131		
CAS No.:	1414976-20-7		
Molecular Formula:	C ₃₆ H ₄₇ ClN ₈ O ₃		
Molecular Weight:	675.26		
Target:	CGRP Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : 50 mg/mL (74.05 mM; Need ultrasonic)
 DMSO : 50 mg/mL (74.05 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.4809 mL	7.4046 mL	14.8091 mL
	5 mM	0.2962 mL	1.4809 mL	2.9618 mL
	10 mM	0.1481 mL	0.7405 mL	1.4809 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (3.08 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 1.25 mg/mL (1.85 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 1.25 mg/mL (1.85 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Vazegepant (BHV-3500) hydrochloride is a highly soluble CGRP receptor antagonist (hCGRP K_i= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation^{[1][2][3]}.

IC₅₀ & Target

Ki: 0.023 nM (hCGRP)^[3]

REFERENCES

- [1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. *Curr Opin Neurol.* 2020;33(3):309-315.
- [2]. Mehta PP, et al. Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications. *Am J Med Sci.* 2021;361(5):557-566.
- [3]. Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. *Curr Opin Neurol.* 2020;33(3):309-315.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA